SalutarisMD is developing a minimally invasive ophthalmic technology for the treatment of Wet AMD. The technology delivers a single dose of brachytherapy.
Wet Age-related Macular Degeneration (Wet AMD) has a profound impact on patient quality of life and imposes a considerable financial burden on healthcare systems. There is a compelling need for new therapies that improve visual outcomes and lower the burden of care by reducing the need for repeated monthly injections and eliminating or extending the period between treatments.
SalutarisMD is developing a minimally invasive ophthalmic technology for the treatment of Wet AMD. The technology delivers a single dose of brachytherapy. Brachytherapy involves the placement of a therapeutic radioisotope inside or next to the area requiring treatment and has shown utility in the clinical management of many diseases.
SalutarisMD was honored by AZBio in 2016 with an AZBio Fast Lane Award.
Click here for more stories about SalutarisMD
Metro Week is a Southern Arizona focused news and public affairs program produced and hosted by Vanessa Barchfield.